{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:35:59Z","timestamp":1756895759943,"version":"3.38.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.2169\/internalmedicine.3593-24","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:10:27Z","timestamp":1723068627000},"page":"775-779","source":"Crossref","is-referenced-by-count":3,"title":["Successful Maintenance Therapy with Intravenous Immunoglobulin to Reduce Relapse Attacks and Steroid Dose in a Patient with Refractory Myelin Oligodendrocyte Glycoprotein Antibody-positive Optic Neuritis"],"prefix":"10.2169","volume":"64","author":[{"given":"Yui","family":"Kamijo","sequence":"first","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Usuda","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagaaki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagano Prefectural Rehabilitation Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuhiko","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagano Prefectural Rehabilitation Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kasamatsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagano Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015.","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ratelade J, Zhang H, Saadoun S, et al. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123: 861-872, 2012.","DOI":"10.1007\/s00401-012-0986-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ratelade J, Asavapanumas N, Ritchie AM, et al. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol 126: 699-709, 2013.","DOI":"10.1007\/s00401-013-1172-z"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381: 614-625, 2019.","DOI":"10.1056\/NEJMoa1900866"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. New Engl J Med 381: 2114-2124, 2019.","DOI":"10.1056\/NEJMoa1901747"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19: 402-412, 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet (London) 394: 1352-1363, 2019.","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19: 298-306, 2020.","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90: e1858-e1869, 2018.","DOI":"10.1212\/WNL.0000000000005560"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82: 474-481, 2014.","DOI":"10.1212\/WNL.0000000000000101"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140: 3128-3138, 2017.","DOI":"10.1093\/brain\/awx276"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13: 280, 2016.","DOI":"10.1186\/s12974-016-0718-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89: 127-137, 2018.","DOI":"10.1136\/jnnp-2017-316880"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pandit L, Sato DK, Mustafa S, et al. Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Transl Clin 2: 2055217316675634, 2016.","DOI":"10.1177\/2055217316675634"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95: e111-e120, 2020.","DOI":"10.1212\/WNL.0000000000009758"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Takai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143: 1431-1446, 2020.","DOI":"10.1093\/brain\/awaa102"},{"key":"17","unstructured":"17. Chen JJ, Huda S, Hacohen Y, et al. Association of maintenance Intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 79: 518-525, 2022."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. L\u00fcnemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat Rev Neurol 11: 80-89, 2015.","DOI":"10.1038\/nrneurol.2014.253"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yoshimura S, Isobe N, Matsushita T, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84: 29-34, 2013.","DOI":"10.1136\/jnnp-2012-302925"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Azumagawa K, Nakashima I, Kaneko K, et al. A nation-wide survey of Japanese pediatric MOG antibody-associated diseases. Brain Dev 43: 705-713, 2021.","DOI":"10.1016\/j.braindev.2021.01.008"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3593-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:34:34Z","timestamp":1740800074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/5\/64_3593-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3593-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"article-number":"3593-24"}}